2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1752

IL-23 Promotes the Generation of DNT Cells and Shifts the Balance Between IL-2 and IL-17 Production in Murine and Human SLE
Abstract Number: 1753

Signal Transducer and Activator of Transcription (STAT) 3 Regulates Tcrαβ+CD4-CD8- T Cells in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1754

Double-Negative T (DNT) Cell over-Expressing PD-1 and Helios Is Responsible for Lupus Tissue Injury in Systemic Lupus Erythematosus (SLE): Direct Proof That Increased Interferon Alpha (IFNα) Expression Is Sufficient to Induce SLE in Ifnα-Transgenic Mice
Abstract Number: 1755

Dendritic Cell-Specific Loss of Caspase 8 Incites Symptoms of Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 1756

Novel Role of Rho Kinase in Neutrophil Netosis during UVB Induced-Skin Inflammation
Abstract Number: 1757

Association of the Lupus Low Disease Activity State (LLDAS) with Health-Related Quality of Life
Abstract Number: 1758

Physical Activity and Sedentary Behaviour in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1759

Sleep Disturbance Is Associated with Worsening Patient-Reported Outcomes over Two Years in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1760

Systemic Lupus Erythematosus in Immigrants: Results from the 1000 Canadian Faces of Lupus Study
Abstract Number: 1761

Fatigue in Patients with Systemic Lupus Erythematosus Is Independent of Their Disease Activity but Dependent on Their Damage Accrual and Body Mass Index
Abstract Number: 1762

Systemic Lupus Erythematosus and the Evaluation of Poor Sleep
Abstract Number: 1763

Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus Following 7 Years of Treatment Exposure: Impact of Clinical Characteristics over Time
Abstract Number: 1764

Effect of Disease Remission on Organ Damage and Quality of Life in Chinese Patients with Systemic Lupus Erythematosus
Abstract Number: 1765

Minimal Clinically Important Differences for Generic Patient Reported Outcomes Tools in SLE
Abstract Number: 1766

Impact of Depression on SLE Flares

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].